Immune Safety Avatar
Nonclinical mimicking of the immune system effects of immunomodulatory therapies
The imSAVAR Vision
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for the integrated nonclinical assessments of safety and efficacy of immunomodulatory therapeutic modalities.
The imSAVAR project is a pioneering initiative funded by the Innovative Medicines Initiative (IMI), dedicated to enhancing the nonclinical safety assessment of immunotherapies.
The primary objective is the creation of a platform to significantly improve the prediction of potential side effects and thereby the safety and efficacy of immunomodulatory therapeutics. We want to achieve that by developing fit-for-purpose nonclinical models with high transferability from laboratory settings to real-world applications.
As partners from the private sector, pharma, regulators, and technology providers closely collaborate in this consortium, imSAVAR will benefit the field of immune safety evaluation. Through these concerted efforts, imSAVAR aims to positively impact the field of immune safety evaluation and pave the way for the future of immunomodulatory therapeutics.
Upcoming Events
“If we really want to move forward with these modern immunomodulatory therapies we need much more research on predictive markers and predictive models. With the imSAVAR project we aim to tackle the challenge of a better understanding of the complexity of the human immune system.”
Ulrike Köhl / Coordinator
“The imSAVAR team plans to characterise a range of innovative human-relevant models and biomarkers to enhance translational safety assessment of immunomodulatory therapeutics and ultimately lead to the development of safer efficacious medicines for patients.”
Jonathan Moggs / Coordinator
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Forum
Engage in lively discussions and help built up a strong imSAVAR stakeholder community.
Learn more about the imSAVAR project
Concept
Read more about our challenges, approach, objectives and the impact we want to make.
Consortium
The interdisciplinary imSAVAR consortium consists of 28 international partners from 11 nations.
Latest News
Announcing Our Special Issue on Innovative Approaches in Preclinical Safety Assessment
We are pleased to announce the publication of our special issue dedicated to innovative approaches in the preclinical safety assessment of immunomodulatory biotherapeutics. This milestone has been achieved through
6th imSAVAR Consortium Meeting – November 2024
The 6th Consortium Meeting of imSAVAR was successfully held at Fraunhofer IZI in Leipzig, closely following the Leipzig Immune Oncology (LION) Conference 2024. This timing allowed us to seamlessly
Recap of the Disease Map Community Meeting in Luxembourg
Last month, the imSAVAR project joined our partners from the University of Luxembourg at the 8th Disease Maps Community Meeting in Belval, Luxembourg, to conduct the first imSAVAR symposium.